(OP:NUMIF)

0.0197 +0.0034 (+20.86%)

Delayed Quote Updated: 3:12 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NUMIF

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions ↗

November 15, 2024

Numinus Wellness sells U.S. clinics to Stella for $3.5M, in a partnership to develop tech-driven solutions for mental health providers.

Via Benzinga

MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward? ↗

September 12, 2024

Via Benzinga

Psychedelics Co. Numinus Narrows Loss In Q3, Reports QoQ Decrease In Revenue, Gross Profit ↗

July 12, 2024

Psychedelics-focused mental health care company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), announced on Thursday its third quarter financial results for the three months ended May 31, 2024."In...

Via Benzinga

Psychedelics-Focused Numinus Plans To Leverage This AI Technology Via New Strategic Acquisition ↗

June 22, 2024

Psychedelics-focused mental healthcare company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23) plans to take over MedBright AI Investments Inc. (CSE: MBA).The proposed transaction comes as...

Via Benzinga

Topics Artificial Intelligence

Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends ↗

April 15, 2024

Via Benzinga

Two Top Biotechs Forge MDMA Supply Deals For Clinical Research ↗

March 26, 2024

Via Benzinga

Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions ↗

March 25, 2024

Via Benzinga

Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review ↗

March 16, 2024

Via Benzinga

Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗

February 15, 2024

Via Benzinga

Why Is MindMed (MNMD) Stock Up 8% Today? ↗

February 12, 2024

MindMed and other psychedelic stocks are rising today on news of an FDA priority review. Here's what this means for MNMD stock and its peers.

Via InvestorPlace

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗

January 27, 2024

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...

Via Benzinga

Numinus Wellness Continues Tight Expense Management With Strategic Reviews Underway ↗

January 18, 2024

Psychedelics mental healthcare company Numinus Wellness (OTCQX: NUMIF) posted its financial results for the three months ended Nov. 30, 2023. Q1 numbers show:

Via Benzinga

30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond ↗

January 10, 2024

The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health...

Via Benzinga

Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More ↗

December 05, 2023

Defense Dept. Funds Ketamine Study For PTSD Treatment

Via Benzinga

Numinus Reports Q4 & Full Year Fiscal 2023 Results, Including Greatly Reduced Cash Burn Rate ↗

November 30, 2023

Psychedelic therapy clinic provider Numinus Wellness (TSX:NUMI) (OTC: NUMIF) announced

Via Benzinga

Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News ↗

September 15, 2023

The long-awaited psychedelic-assisted treatment alternative for Post-Traumatic Stress Disorder (PTSD) is moving closer to federal approval.

Via Benzinga

NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years ↗

September 12, 2023

NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.

Via Benzinga

Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

July 26, 2023

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

Via FinancialNewsMedia

Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

July 14, 2023

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Small Cap Growth Virtual Investor Conference Agenda Announced for July 13th

July 10, 2023

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University ↗

June 20, 2023

Numinus Wellness (OTCMKTS: NUMIF) with support from the Multidisciplinary Association for Psychedelic Studies (MAPS) will utilize Optimi Health’s (OTCMKTS: OPTHF) Good Manufacturing Practice...

Via Benzinga

Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study ↗

June 16, 2023

In a prelude to what is hoped will be regulatory approval of MDMA-assisted therapy in the U.S. and Canada, Numinus Wellness Inc. (OTC: NUMIF) has taken steps to get out in front of the curve.

Via Benzinga

Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study ↗

June 05, 2023

Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud

Via Benzinga

Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More ↗

May 31, 2023

Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics...

Via Benzinga

Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD ↗

May 30, 2023

Numinus Wellness Inc.’s (OTCMKTS: NUMIF) wholly-owned contract research organization Cedar Clinical Research has commenced a new study on COMPASS Pathways’ (NASDAQ: CMPS) psilocybin therapy for...

Via Benzinga

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗

April 24, 2023

LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...

Via Benzinga

Numinus Wellness CEO Payton Nyquvest On Q2 2023 Financial Results And Numinus Network ↗

April 19, 2023

On this new Psychedelic Series Podcast, TDR Founder Shadd Dales spoke with Payton Nyquvest, CEO of Numinus Wellness Inc. (OTC: NUMIF).

Via Benzinga

Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More ↗

April 17, 2023

Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules

Via Benzinga

Numinus Q2 2023: 581% Revenue Growth, 820% In Gross Profit And Strong Cash Position ↗

April 14, 2023

Psychedelics mental healthcare company Numinus Wellness Inc. (OTCQX: NUMIF) announced its financial results for the three and six months ended Feb. 28, 2023. Q2 numbers show: Total cash of $14.7...

Via Benzinga

EXCLUSIVE: Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth' ↗

April 13, 2023

“Investing in real estate can help expand experiential medicines like ketamine and MDMA for treating PTSD and build infrastructure for upcoming FDA-approved therapies,” said Daniel Carcillo, founder...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.